Curated News
By: NewsRamp Editorial Staff
October 06, 2026
Quantum BioPharma Partners with Thermo Fisher for Lucid-MS Phase 2 Trial
TLDR
- Quantum BioPharma advances its first-in-class MS drug Lucid-MS into Phase 2, gaining a potential edge in progressive MS treatment.
- Quantum BioPharma partners with Thermo Fisher to start a Phase 2 trial of Lucid-MS, which inhibits PAD2 to prevent myelin degradation.
- Quantum BioPharma's Phase 2 trial of Lucid-MS offers hope for new treatments for progressive multiple sclerosis, aiming to improve patients' lives.
- Quantum BioPharma's Lucid-MS targets PAD2, an enzyme involved in myelin degradation, and is now moving into a Phase 2 clinical trial.
Impact - Why it Matters
This news matters because it marks a critical step forward in the development of a potential first-in-class treatment for multiple sclerosis, a chronic and often debilitating disease affecting millions worldwide. The collaboration with Thermo Fisher's PPD Clinical Research Business brings significant clinical trial expertise to the table, which could accelerate the timeline for bringing Lucid-MS to market. If successful, Lucid-MS could offer a new mechanism of action by targeting PAD2 to inhibit demyelination, potentially providing neuroprotection for patients with progressive forms of MS who currently have limited treatment options. For investors, this agreement signals progress and validates the company's approach, potentially impacting Quantum BioPharma's stock value and future partnerships.
Summary
Quantum BioPharma (NASDAQ: QNTM) has entered into a Study Start-Up Agreement (SUA) with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-21-302 (Lucid-MS) for multiple sclerosis (MS). The agreement initiates formal study start-up activities following FDA clearance to proceed with the trial. Thermo Fisher will support study start-up and related clinical research services through its PPD™ Clinical Research Business. According to the press release, the randomized, double-blind, placebo-controlled Phase 2 trial will evaluate the efficacy, safety, and tolerability of Lucid-MS in people with progressive forms of MS using clinical and radiological endpoints.
Lucid-MS is an investigational, first-in-class New Chemical Entity designed to provide neuroprotection by inhibiting demyelination through targeting protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. The company also invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake and royalty rights.
For more details, see the full press release. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Quantum BioPharma Partners with Thermo Fisher for Lucid-MS Phase 2 Trial
